ELI LILLY & Co (LLY) · Oct 29, 2026 · Earnings
Beat — Non-GAAP EPS $7.48 vs ~$6.67 consensus; revenue $24.4B vs ~$22.6B consensus
Eli Lilly earnings beat sharply on Mounjaro and Zepbound demand, while revenue guidance jumps despite acquisition-related EPS charges.
Lilly is still building around a fast-growing cardiometabolic franchise: Mounjaro and Zepbound represented 65% of revenue in the first half of 2026, while the company is expanding manufacturing and broadening its pipeline beyond GLP-1 drugs. The quarter materially exceeded the market’s setup. Revenue reached $24.4 billion, roughly $1.8 billion above the published consensus near $22.6 billion, while non-GAAP EPS was $7.48 versus roughly $6.67 expected. The beat was driven by volume, not just accounting: worldwide volume rose 53%, with Mounjaro revenue up 65% and Zepbound up 49% (Selected Products).
| Metric | Q3 2026 | Q3 2025 | Consensus / Prior guidance |
|---|---|---|---|
| Revenue (Financial Highlights) | $24,397M (+39%) | $17,601M | ~$22,600M consensus |
| Non-GAAP EPS (Financial Highlights) | $7.48 (+7%) | $7.02 | ~$6.67 consensus |
| Mounjaro revenue (Selected Products) | $10,723M (+65%) | $6,515M | |
| Zepbound revenue (Selected Products) | $5,352M (+49%) | $3,588M | |
| FY revenue guidance (2026 Financial Guidance) | $91B-$92B | $85B-$87B prior | |
| FY non-GAAP EPS guidance (2026 Financial Guidance) | $35.00-$36.00 | $35.50-$36.50 prior |
Management raised the business outlook much more than the headline EPS range suggests. Full-year revenue guidance rose by $5.5 billion at the midpoint, and underlying non-GAAP EPS guidance increased by $4.07 at the midpoint. The reported EPS range nevertheless moved down because Lilly absorbed $4.57 per share of acquired in-process R&D charges from Q3 deals.
The underlying growth engine is broadening, but pricing is the clear offset. Lilly delivered 53% volume growth worldwide, while realized prices fell 15%; outside the U.S., price pressure was 29%, primarily after Mounjaro entered China’s reimbursement list. That trade-off did not prevent gross margin from improving to 83.9%, but it shows that future growth increasingly depends on adding volume and new products rather than simply holding price. 〔0〕
The pipeline and regulatory progress add support to the next leg of the story. Lilly received multiple U.S. approvals, including expanded Mounjaro cardiovascular use and new indications for Jaypirca and Inluriyo, while retatrutide produced positive head-to-head results against Ozempic 2 mg. Those developments were already part of the broader setup, so they reinforce rather than redefine the quarter’s main message: current demand is beating expectations while future growth options are expanding. 〔1〕
Bottom line: This was a genuine earnings and revenue beat, backed by exceptional Mounjaro and Zepbound volume and a large revenue-guidance increase. The lower reported EPS range is mostly deal-accounting noise; the underlying operating outlook improved meaningfully, although pricing pressure is becoming more visible.
Retatrutide Phase 3 trials start in Q4 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!